The Childhood Cancer Survivorship, Treatment, Access, and Research (STAR) Act (formerly HR331) would expand opportunities for childhood cancer research, improve efforts to identify and track childhood cancer incidences, enhance the quality of life for childhood cancer survivors, and ensure publicly accessible expanded access policies that provide hope for patients who have run out of options.
The original STAR Act passed the House of Representatives on December 6, 2016 and went to the Senate where it was too late to get voted on before the end of the session. The process has to be started all over in order to pass in the 115th Congress. The Star Act was officially reintroduced on February 2, 2017 by Rep. Michael McCaul in the House as HR. 820 and by Senator Jack Reed as S. 292. With House passage last year and the fact we gained a lot of new support in the Senate, we fully expect that passage should come in the first quarter of 2017. What should you do now? Contact your Representative and Senators and ask each of them to cosponsor the STAR Act, HR 820 (House of Representatives) and S 292 (Senate).
Contact Your Representative and Senators HERE. Tell your Representative and Senators why the Childhood Cancer STAR Act is important to you and how it can affect you, your child, and the entire childhood cancer community. Tell your story without filters. Tell it like only you can. Make it very personal, enclose a picture of your child. Ask them for action. Ask them to respond to your request. You, your friends, and family members calling and writing letters and encouraging others to do so will be very helpful in passing the STAR Act for 2017.
House Sponsors: H820 Representative Michael McCaul (R-TX), Jackie Speier (D-CA), Mike Kelly (R-PA), G.K. Butterfield (D-NC)
Senate Sponsors: S292 Senators Jack Reed (D-RI), Shelley Moore Capito (R-WV), Chris Van Hollen (D-MD), Johnny Isakson (R-GA)
The Childhood Cancer Survivorship, Treatment, Access, and Research (STAR) Act would expand opportunities for childhood cancer research, improve efforts to identify and track childhood cancer incidences, enhance the quality of life for childhood cancer survivors, and ensure publicly accessible expanded access policies that provide hope for patients who have run out of options.
Expanding Opportunities for Childhood Cancer Research: Due to the relatively small population of children with cancer and the geographic distance between these children, researching childhood cancer can be challenging. As such, the Childhood Cancer STAR Act would authorize the National Cancer Institute (NCI) to expand existing efforts to collect biospecimens for childhood cancer patients enrolled in NCI-sponsored clinical trials to collect and maintain relevant clinical, biological, and demographic information on all children, adolescents, and young adults with cancer.
Improving Childhood Cancer Surveillance: Building upon previous efforts, this bill would authorize grants to state cancer registries to identify and track incidences of child, adolescent, and young adult cancer. This funding would be used to identify and train reporters of childhood cancer cases, secure infrastructure to ensure early reporting and capture of child cancer incidences, and support the collection of cases into a national childhood cancer registry.
Improving Quality of Life for Childhood Cancer Survivors: Unfortunately, even after beating cancer, as many as two-thirds of survivors suffer from late effects of their disease or treatment, including secondary cancers and organ damage. This legislation would enhance research on the late effects of childhood cancers, including a study on insurance coverage and payment of care for childhood cancer survivors; improve collaboration among providers so that doctors are better able to care for this population as they age; and establish a new pilot program to begin to explore innovative models of care for childhood cancer survivors.
Ensuring Patients Access to Publicly Available Compassionate Use Policies: Compassionate use– the process by which a patient with a serious or life-threatening illness can be granted access to therapies still in development and outside of the clinical trial setting, when there is no comparable alternative – is often challenging for patients and their doctors to navigate. This legislation would ensure that pharmaceutical companies have publicly accessible compassionate use policies and would require FDA to finalize its guidance and address regulatory uncertainties for industry on the issue.
Ensuring Pediatric Expertise at the National Institutes of Health (NIH): The Childhood Cancer STAR Act would require the inclusion of at least one pediatric oncologist on the National Cancer Advisory Board and would improve childhood health reporting requirements to include pediatric cancer.
HR. 820 Cosponsors: 240 cosponsors (142D, 98R)
Senate S. 292 Cosponsors: 7 cosponsors (4R, 3D)